Re-test your knowledge
Re-test your knowledge
Summary
Now that you have completed Module 3 Clinical data for QUVIVIQ™ (daridorexant), you should have a better understanding of unmet needs in patients with chronic insomnia, and of the clinical data for the use of QUVIVIQ™ in these patients. To re‑test your knowledge, answer the questions below and see how your score has improved.
Ready for the next module?
Addressing patient concerns
NICE: National Institute for Health and Care Excellence
QUVIVIQ™ is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.4
This information is intended for UK healthcare professionals.
Adverse events must be reported. Healthcare professionals are asked to report any suspected adverse reactions via www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to ds.safety.uk@idorsia.com
References
- Mignot E, Mayleben D et al. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double‑blind, placebo‑controlled, phase 3 trials. Lancet Neurol 2022;21(2):125‑139
- Morin C M, Drake C L et al. Insomnia disorder. Nat Rev Dis Primers 2015;1:15026
- Hudgens S, Phillips‑Beyer A et al. Development and validation of the insomnia daytime symptoms and impacts questionnaire (IDSIQ). Patient 2021;14(2):249‑268
- QUVIVIQ™ Idorsia Pharmaceuticals Ltd, Summary of Product Characteristics
- National Institute for Health and Care Excellence (NICE). Technology appraisal guidance 922. Daridorexant for treating long‑term insomnia, 18 October 2023. Available at: nice.org.uk. Accessed August 2025
© NICE 2023 Daridorexant for treating long-term insomnia. Available from www.nice.org.uk/guidance/ta922. All rights reserved. Subject to Notice of rights.
NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/ publication.
UK-DA-00655 | Date of preparation: September 2025
